2-(2-Phenylethyl)-2H-1,2,3-benzotriazole, 500mg

(R)-2-ethylpyrrolidine hydrochloride, 98%, 5g

epsilon-Benzyl-L-glutamic acid carboxylic anhydride, 95.0%, 5g

4-(4-Fluorophenyl)butan-2-one, 97.0%, 100mg

3-Acetylphenylboronic acid, 97.0%, 100g

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-carbaldehyde, 98.00%, 10g

2-(4-Nitrophenyl)ethyl Bromide>98.0%(GC)25g

2-(Aminomethyl)-4-bromophenol Hydrochloride, 95.0%, 5g

4-Bromophthalazin-1(2H)-one, 95.0%, 100mg

N-tert-Butylbenzamide, 95%, 1g

4-[2-N,N-Dimethylaminoethoxy]bromobenzene, 98.0%, 250mg

METHYL 2,4-DIHYDROXY-5-ISOPROPYLBENZOATE, 95.0%, 10g

Plan PLPH S100x/1.25 phase contrast objective